The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy

Cell Mol Immunol. 2019 Oct;16(10):791-799. doi: 10.1038/s41423-018-0056-5. Epub 2018 Jul 4.

Abstract

The chemokine receptor CCR7 and its ligands CCL19 and CCL21 guide the homing and positioning of dendritic and T cells in lymphoid organs, thereby contributing to several aspects of adaptive immunity and immune tolerance. In the present study, we investigated the role of CCR7 in the pathogenesis of collagen-induced arthritis (CIA). By using a novel anti-human CCR7 antibody and humanized CCR7 mice, we evaluated CCR7 as a target in this autoimmune model of rheumatoid arthritis (RA). Ccr7-deficient mice were completely resistant to CIA and presented severely impaired antibody responses to collagen II (CII). Selective CCR7 expression on dendritic cells restored arthritis severity and anti-CII antibody titers. Prophylactic and therapeutic treatment of humanized CCR7 mice with anti-human CCR7 mAb 8H3-16A12 led to complete resistance to CIA and halted CIA progression, respectively. Our data demonstrate that CCR7 signaling is essential for the induction of CIA and identify CCR7 as a potential therapeutic target in RA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / metabolism
  • Arthritis, Experimental / metabolism*
  • Arthritis, Rheumatoid / metabolism*
  • Autoantibodies / metabolism
  • Collagen Type II / immunology
  • Dendritic Cells / immunology*
  • Disease Progression
  • Disease Resistance
  • Humans
  • Mice
  • Mice, Knockout
  • Molecular Targeted Therapy
  • Receptors, CCR7 / genetics
  • Receptors, CCR7 / immunology
  • Receptors, CCR7 / metabolism*

Substances

  • Antibodies, Monoclonal
  • Autoantibodies
  • CCR7 protein, human
  • Ccr7 protein, mouse
  • Collagen Type II
  • Receptors, CCR7